

## Notice of Special Interest (NOSI):

# Research on Interprofessional Teamwork and Coordination During Cancer Diagnosis and Treatment NOT-CA-22-014

*Healthcare Delivery Research Program (HDRP)*


*Division of Cancer Control & Population Sciences (DCCPS)*

January 14, 2022



<https://healthcaredelivery.cancer.gov/>

# Using WebEx and Webinar Logistics



- All lines will be in listen-only mode
- Submit questions at any time using the Q&A or Chat Panel and select *All Panelists*
- You may need to activate the appropriate box using the floating navigation panel. Found on the center of your screen



- This webinar is being recorded

# Webinar presenters

Sallie J. Weaver, PhD, MHS

Health Systems & Interventions Research Branch

Healthcare Delivery Research Program

Division of Cancer Control & Population Sciences NCI

[sallie.weaver@nih.gov](mailto:sallie.weaver@nih.gov)



Veronica Chollette, RN, MS

Health Systems & Interventions Research Branch

Healthcare Delivery Research Program

Division of Cancer Control & Population Sciences NCI

[cholletv@nih.gov](mailto:cholletv@nih.gov)



# Overview

- Background
- Notice of Special Interest (NOSI) Details
  - What is a NOSI?
  - Goals and scope
  - Application details
  - Resources
- Questions
  - NOTE: Questions about specific aims will not be addressed

# Background

*NCI Healthcare Delivery Research Program*

# NCI DCCPS organizational structure

Division of Cancer Control and Population Sciences (DCCPS)

*Office of Cancer Survivorship  
Implementation Science*

**Healthcare  
Delivery  
Research  
Program (HDRP)**


**Behavioral  
Research  
Program (BRP)**

**Epidemiology  
and Genomics  
Research  
Program (EGRP)**

**Surveillance  
Research  
Program (SRP)**

# Healthcare Delivery Research Program (HDRP)

Advancing innovative research to improve the delivery of cancer-related care



<https://healthcaredelivery.cancer.gov>

# Background

*Research on Interprofessional Teamwork and Coordination During  
Cancer Diagnosis and Treatment  
NOT-CA-22-014*



# Suboptimal coordination during cancer treatment is a public health problem

- **Common:** Significant proportion of cancer patients experience treatment coordination issues
- **Costly:** Poor coordination affects costs, workload, adherence, outcomes, medical errors
- **Complex:** Increasing range of disciplines, settings engaged
  - Lung, GI, breast, male & female reproductive cancers: 14 to 17 clinicians
  - Coordination challenges amplified for underserved populations in community settings
- Unclear which team characteristics and teamwork processes produce better care quality, patient outcomes, utilization

# Notice of Special Interest (NOSI) Details

*Research on Interprofessional Teamwork and Coordination During  
Cancer Diagnosis and Treatment*

*NOT-CA-22-014*

# What is a notice of special interest (NOSI)?

- Notice posted in the NIH guide that institutes and centers can use to share, update research priorities
- Points to funding opportunity announcements (FOAs) through which investigators can apply
  - Usually NIH or DCCPS parent announcements
  - Standing study sections, no set-aside \$
- Before 2019: Used by some NIH institutes and centers
- 2019 and beyond: NOSI replaces non-parent Program Announcements (PA)

# NOT-CA-22-014: Goal

Highlight interest in receiving investigator-initiated grant applications focused on understanding and improving interprofessional teamwork and coordination during cancer diagnosis and treatment

## **Focus: Research that...**

- Identifies effective strategies for improving performance of interprofessional cancer care teams during cancer diagnosis and treatment
- Addresses care coordination challenges:
  - Within and/or between care settings (e.g., between tertiary care and community settings)

## Areas of scientific interest for NOT-CA-22-014

Research encouraged through this Notice includes, but is not limited to, studies that:

- Identify modifiable features of care team **structure** (e.g., care team composition or organization), associated with differences in cancer care quality and patient outcomes
- Identify modifiable features of care team **processes** (e.g., decision making, communication, coordination behaviors, collaboration, leadership) associated with differences in cancer care quality and patient outcomes

## Areas of scientific interest for NOT-CA-22-014 (cont.)

- Identify characteristics at the patient, caregiver, care team, delivery organization, health system, and/or community levels that influence the functioning and effectiveness of interprofessional cancer care teams
- Develop and test interventions designed to improve cancer care quality and patient outcomes by **modifying** the structure and/or functioning of interprofessional teams
- Develop and test interventions designed to improve cancer care quality and patient outcomes by **engaging** patients and caregivers as members of their cancer care team

## How do I submit an application in response to NOT-CA-22-014?

- Submit applications for this initiative using one of the following funding opportunity announcements (FOAs)

	<b>Funding Opportunity Announcement</b>		<b>First Available Due Date</b>
<b>R03</b>	<a href="#">PAR-20-052</a>	NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03 Clinical Trial Optional)	Feb 24, 2022
	<a href="#">PA-20-200</a>	NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)	March 16, 2022
<b>R21</b>	<a href="#">PAR-21-341</a>	Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)	June 07, 2022
	<a href="#">PA-20-195</a>	NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)	Feb 16, 2022
	<a href="#">PA-20-194</a>	NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)	Feb16, 2022
<b>R01</b>	<a href="#">PAR-21-190</a>	Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)	March 07, 2022
	<a href="#">PAR-21-035</a>	Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)	Feb 5, 2022
	<a href="#">PA-20-185</a>	NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)	Feb 5, 2022
	<a href="#">PAR-21-038</a>	Stephen I. Katz Early Stage Investigator Research Project Grant (clinical trial not allowed)	Janu 26, 2022
<b>P01</b>	<a href="#">PAR-20-077</a>	National Cancer Institute Program Project Applications (P01 Clinical Trial Optional)	May 25, 2022

## How do I submit an application in response to NOT-CA-22-014?

### **How do I indicate my application is in response to NOT-CA-22-014?**

Applicants must include "NOT-CA-22-014" (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 application form

- Applications without this information in box 4B will not be considered for this initiative

### **What if the Funding Announcement listed in the NOSI that I want to apply to is expiring?**

Applications may be submitted to any of the reissuances of the funding announcements listed in NOT-CA-22-014 through October 9, 2024



# NOT-CA-22-014: R03 NIH/NCI Small Grants Program

- Small research projects requiring short time period, limited resources
- Direct costs up to \$50,000 per year, project period up to 2 years
- Submit R03 projects responsive to NOT-CA-22-014 through:
  - [PAR-20-052 NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 \(NCI Omnibus R03 Clinical Trial Optional\)](#)
  - **\*\*SEE PAR-20-052 for DUE DATES\*\***
  - [PA-20-200 NIH Small Research Grant Program \(Parent R03 CT Not Allowed\)](#)

# NOT-CA-22-014 : R21 NIH/NCI Exploratory/Developmental Research

- Exploratory or developmental studies, break new ground or extend previous discoveries toward new directions or applications
- Project period up to 2 years, total direct cost budget across entire project may not exceed \$275,000
- Submit R21 projects responsive to NOT-CA-22-014 through:
  - [PAR-21-341 Exploratory Grants in Cancer Control \(R21 Clinical Trial Optional\)](#)
  - [PA-20-195 NIH Exploratory/Developmental Research Grant Program \(Parent R21 Clinical Trial Not Allowed\)](#)
  - [PA-20-194 NIH Exploratory/Developmental Research Grant Program \(Parent R21 Clinical Trial Required\)](#)

# NOT-CA-22-014: R01 NIH/DCCPS Research Project Grant

- Supports a discrete, specified research project
- No specific dollar limit
  - Advance permission required for  $\geq$ \$500K direct costs in any year, minimum of 8 weeks before targeted receipt date
- 3 to 5 year project period
- Standard due dates
- Clinical trial? Use [PAR-21-035 Cancer Prevention and Control Clinical Trials Grant Program \(R01 Clinical Trial Required\)](#)
- No clinical trial? Use [PA-20-185 NIH Research Project Grant \(Parent R01 Clinical Trial Not Allowed\)](#)

# NOT-CA-22-014: NCI DCCPS Modular R01 Research Project Grant

- Supports a discrete, specified research project
- Focus: Smaller scale studies
- Direct costs for any year may NOT exceed \$250K
- 2 to 5 year project period
- 2 due dates per year: March & November
- Submit modular R01 projects responsive to NOT-CA-22-014 through:
  - [PAR-21-190: Modular R01s in Cancer Control and Population Sciences \(R01 Clinical Trial Optional\)](#)

# Grant mechanism: P01 NCI Program Project Grant

- Supports integrated, multi-project research projects involving a number of independent investigators who share knowledge and common resources
- 3 research projects and administrative core
- Each project contributes or is directly related to the common theme of the overall programmatic research goal, thus forming a cohesive and well-defined system of research activities and projects
- Pre-submission meeting required 6 to 9 months before receipt date
- [PAR-20-077 National Cancer Institute Program Project Applications \(P01 Clinical Trial Optional\)](#)

## Other NOT-CA-22-014 considerations

- Research should advance actionable knowledge about how to design and carry out effective, efficient interprofessional team-based cancer care that improves quality and patient outcomes
- Not required, but encouraged: Research focused on needs of racial/ethnic minority, medically underserved, or low-income populations and/or those receiving care in community settings (e.g. community-based cancer centers or clinics)

# Application requirements

- All instructions in the [SF424 \(R&R\) Application Guide](#) and the funding opportunity announcement used for submission must be followed
- **Applicants must include “NOT-CA-22-014” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form**
  - Applications without this information in box 4B will not be considered for this initiative
- Carefully read the entire funding opportunity announcement for which you are applying

# How will applications to NOT-CA-22-014 be reviewed?

- All applications will be reviewed by a standing study section convened by the [NIH Center for Scientific Review \(CSR\)](#)
- You may include (optional) an [Assignment Request Form](#) with your application to:
  - Express preferences for particular study sections
  - Express preferences for a specific institute (e.g., NCI)
  - Let NIH know of potential reviewers who you feel might have a conflict of interest with your application
  - Describe expertise needed to review your application; do not provide names
- The [CSR Assisted Referral Tool \(ART\)](#) can help recommend potentially appropriate study sections for your application



# Standard review criteria

*Overall impact*

## **Scored review criteria**

- Significance
- Investigators
- Innovation
- Approach
- Environment

## **Additional review criteria**

- \*Study timeline (for clinical trials)
- Protections for Human Subjects
- Inclusion
- Vertebrate Animals
- Biohazards

## **Additional review considerations**

- Check funding opportunity announcement to see resource sharing plan requirements (e.g., data sharing plan)

## Important dates

- First available submission date: Feb 5, 2022, **but varies based on funding announcement selected, see “Application and Submission Information” section in NOT-CA-22-014**
- Application due dates: See “Application and Submission Information” section in NOT-CA-22-014
- Notice expiration date: October 9, 2024
- Start the process early
- Read NOT-CA-22-014 and eligible funding announcements carefully
- Discuss 1-page summary with program contacts listed in Notice

# Resources

- Today's webinar and FAQ will be posted on our website:

<https://healthcaresdelivery.cancer.gov/media>

- Reach out to NOT-CA-22-014 Program Contacts early:


Sallie Weaver, PhD, MHS

[sallie.weaver@nih.gov](mailto:sallie.weaver@nih.gov)


Veronica Chollette, RN, MS

[cholletv@nih.gov](mailto:cholletv@nih.gov)

# Additional resources




[Special series: NCI-ASCO Teams in Cancer Care papers. Journal of Oncology Practice. Nov 2016; 12\(11\): 955-1147.](#)



<https://healthcaredelivery.cancer.gov/healthcare/>

# Questions?

Please type your questions in the Q & A section on WebEx



Sallie Weaver  
[sallie.weaver@nih.gov](mailto:sallie.weaver@nih.gov)

Veronica Chollette  
[cholletv@nih.gov](mailto:cholletv@nih.gov)